RegeneRx Biopharmaceuticals Profit Margin

RegeneRx Biopharmaceuticals (RGRX) currently reports a profit margin of -2022.11% as of September 2023. That compares with -2326.63% in the prior-year period — up 13.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore RegeneRx Biopharmaceuticals's profit margin history and peer comparisons.

RegeneRx Biopharmaceuticals's profit margin increased from -2326.63% to -2022.11% — a 13.1% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RegeneRx Biopharmaceuticals's profit margin of -2022.11% is lower than the Healthcare sector average of 13.89%. That is roughly 14654.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but RegeneRx Biopharmaceuticals's current -2022.11% should be judged against Healthcare norms (sector average: 13.89%) and against RGRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2022.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for RegeneRx Biopharmaceuticals, and consider following RGRX for alerts when major investors trade the stock.